CD24 and cancer: Interrupting SIPR1α-CD47 or SIGLEC10-CD24 axis by CD47 or CD24 antibodies stimulated TAMs to phagocytose cancer cells and enhanced antitumor T cell responses in mouse models 81, 219, 220.